aTENSION.life develops precision diagnostics for hypertension using a proprietary ALDO+ mass spectrometry platform. Its first product, ALDO+PA, screens for primary aldosteronism from a single blood sample, targeting an underdiagnosed condition affecting 5–10% of hypertensive patients. The ALDO+PA test is currently available in Austria through a partnership with labors.at, with initial customers already implementing the technology in Germany, Switzerland and the US. The company plans to roll out across DACH markets by 2026. The articles highlight a large addressable market—approximately 1.3 billion adults with hypertension worldwide, of whom about 720 million may not receive adequate treatment due to underdiagnosis of specific subtypes. The company announced a USD 3 million seed financing led by Wlanholding that coincided with the appointment of Dr. Werner Lanthaler as chairman.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

May 2025